JNJ-87704916

· Johnson & Johnson Enterprise Innovation Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-87704916, covering 2026-02-13 to 2026-02-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors [Phase 1]